Retrospective observational study of osimertinib and afatinib for patients with advanced EGFR-mutated non-small cell lung cancer.

Retrospective observational study of osimertinib and afatinib for patients with advanced EGFR-mutated non-small cell lung cancer. - Retrospective study of osimertinib and afatinib in EGFR-mutated NSCLC.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041251

Enrollment

300

Registered

2020-07-30

Start date

2020-02-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced non-small cell lung cancer harboring EGFR mutation.

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosed pathologically with non-small cell lung cancer. 2. With EGFR mutation, regardless of subtype of mutation. 3. Recieved afatinib or osimertinib as systemic first-line monotherapy.

Exclusion criteria

Exclusion criteria: 1. Not recieved afatinib or osimertinib as a monotherapy. 2. Recieved chemotherapy or immunotherapy before monotherapy of afatinib/osimertinib as systemic treatment for advanced non-small cell lung cancer. 3. Cases identified as ineligible by investigator.

Design outcomes

Primary

Measure	Time frame
Time to Discontinuation of any EGFR tyrosine kinase inhibitor (TD-TKI)	—

Countries

Japan

Contacts

Public ContactKentaro Ito

Matsusaka Municipal Hospital Department of Respiratory Medicine, Respiratory Center

kentarou_i_0214@yahoo.co.jp+81-598-23-1515

Outcome results